R/R DLBCL

Jun 10, 2025

Abbvie-Genmab’s EPKINLY/TEPKINLY Performance in DLBCL Treatment: The First CD20XCD3 Bispecific Antibody

Apr 16, 2024

Roche’s Columvi Phase III STARGLO Trial; Novartis’ Fabhalta Latest Data; Vertex’s Alpine Immune Sciences Acquisition; Telix Pharmaceuticals’ TLX101-CDx Fast Track Designation; NovelMed’s NM5072 Orphan Drug Designation

Newsletter/Whitepaper